［1］Hammarsten O. Untersuchungen über die Gallen einiger Polarthiere［J］.Phys chem, 1901, 32( 5) : 435-466.
［2］Shoda M. Uber die Ursodeoxycholsaure aus Barengallen und ihre physiologische wirkung［J］. J Biochem, 1927, 42( 7) : 505-507.
［3］日本药局方编辑委员会编纂.《日本药局方》［M］. 第八改正版, 1971.
［4］Okumura M. Clinical studies on dissolution of gallstones using ursodeoxycholic acid［J］. Gastroterol Jpn, 1977, 12( 6) : 469-475.
［5］钟岚, 范建高. 熊去氧胆酸在慢性肝病中的应用及机制［J］.国外医学·消化系疾病分册, 1999, 19( 2) : 91-94.
［6］Rudic JS, Poropat G, Krstic MN, et al. Ursodeoxycholic acid for primary biliary cirrhosis［J］. Lancet, 2000, 355( 9204) : 657-658.
［7］Poropat G, Giljaca V, Stimac D, et al. Bile acids for liver-transplanted patients［J］. Cochrane Database Syst Rev, 2005, 5(3):85-86.
［8］Cheng K, Ashby D, Smyth RL.Ursodeoxycholic acid for cystic fibrosis-related liver disease［J］. Cochrane Database Syst Rev, 2000, 10( 2) : CD000222.
［9］Sinakos E, Marschall HU, Kowdley KV, et al. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis : relation to disease progression［J］. Hepatology,2010,52( 1) : 197-203.
［10］Kotb MA. Ursodeoxycholic acid in neonatal hepatitis and infantile paucity of intrahepatic bile ducts : Review of a historical cohort［J］. Dig Dis Sci, 2009, 54(10) : 2231-2241.
［11］Burnat G, Majka J, Konturek PC. Bile acids are multifunctional modulators of the Barrett's carcinogenesis［J］. J Physiol Pharmacol, 2010, 61( 2) : 185-192.
［12］Anabela P, Rolo, Carlos M, Palmeira, et al.Wallace.Mitochondrially mediated synergistic cell killing by bile acids［J］. Biochim Biophys Acta, 2003, 1637( 1) : 127-132.
［13］Magd A, Kotb. Molecular Mechanisms of Ursodeoxycholic Acid Toxicity & Side Effects : Ursodeoxycholic Acid Freezes Regeneration & Induces Hibernation Mode［J］. Int J Mol Sci, 2012, 13( 7) : 8882-8914.
［14］Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis［J］.Lancet, 2015, 386(10003) : 1565-1575.
［15］European Association for the Study of the Liver. EASL Clinical Practice Guidelines : management of cholestatic liver diseases［J］. J Hepatol 2009, 51(2) : 237-267.
［16］胆汁淤积性肝病诊断治疗专家共识：2015年更新［J］.中国肝脏病杂志（电子版）, 2015, 7(2) : 1-11.
［17］Zhang LN, Shi TY, Shi XH, et al.Eady biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis : results of a 14 year cohort study［J］. Hepatology, 2013, 58(1) : 264-272.
［18］Lammers WJ, van Buuren HR, Hirschfield GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study［J］. Gastroenterology, 2014, 147(16) : 1338-1349.
［19］Ali AH, Lindor KD.Obeticholic acid for the treatment of primary biliary cholangitis［J］.Expert Opin Pharmacother, 2016 , 17(13): 1809-1815.
［20］Jones DE.Obeticholic acid for the treatment ofprimary biliary cirrhosis［J］.Expert Rev Gastroenterol Hepatol, 2016, 10 (10): 1091-1099.
［21］Dyson JK, Hirschfield GM, Adams DH, et al. Novel therapeutic targets in primary biliary cirrhosis［J］.Nat Rev Gastroenterol Hepatol, 2015, 12(3): 147-158.
［22］Czul F, Levy C. Novel Therapies on Primary Biliary Cirrhosis［J］.Clin Liver Dis,2016, 20 (1): 113-130.
［23］Kuiper EM, Hansen BE, Adang RP, et al. Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid［J］. Eur J Gastroenterol Hepatol, 2010, 22(12) : 1495-1502.
［24］Christophe C. Primary Biliary Cirrhosis Beyond Ursodeoxycholic Acid［J］. Semin Liver Dis, 2016, 36(1) : 15-26.
［25］Sclair SN, Little E, Levy C. Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis［J］. Clin Transl Gastroenterol, 2015, 6(8) : e109.
［26］Lindor K, Kowdley K, Luketic V, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis［J］. Hepatology, 2009,50(3): 808-814.
［27］Lindstrom L, Hultcrantz R, Boberg KM, et al. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitisp［J］.Clin Gastroenterol Hepatol , 2013, 11 (7) : 841-846.
［28］Othman MO, Dunkelberg J, Roy PK. Urosdeoxycholic acid in primary sclerosing cholangitis: A meta-analysis and systematic review［J］. Arab J Gastroenterol, 2012, 13(3) : 103-110.
［29］Hansen JD, Kumar S, Lo WK, et al.Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis［J］. Dig Dis Sci, 2013, 58(11) : 3079-3087.
［30］Wunsch E, Trottier J, Milkiewicz M, et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis［J］.Hepatology, 2014, 60 (3): 931-940.
［31］Chazouillères O. Primary sclerosing cholangitis and bile acids［J］. Clin Res Hepatol Gastroenterol, 2012, 36(36S1) : S21-S25.
［32］Triantos CK, Koukias NM, Nikolopoulou VN, et al. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis［J］. Aliment Pharmacol Ther, 2011, 34(8) : 901-910.
［33］Ali AH, Carey EJ, Lindor KD.Current research on the treatment of primary sclerosing cholangitis［J］. Intractable Rare Dis Res, 2015, 4(1): 1-6.
［34］Halilbasic E, Fuchs C, Hofer H, et al. Therapyof Primary Sclerosing Cholangitis-Today and Tomorrow［J］.Dig Dis,2015, 33(2): 149-163.
［35］Costa PC, Barreto CC, Pereira L, et al. Cystic fibrosis-related liver disease: a single-center experience［J］.Pediatr Rep, 2011, 3(21):87-90.
［36］Flass T, Narkewicz MR.Cirrhosis and other liver disease in cystic fibrosis［J］. J Cyst Fibr2013, 12(2) : 116-124.
［37］Sokol RJ, Durie PR. Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group［J］. J Pediatr Gastroenterol Nutr, 1999, 28(1) : S1-S13.
［38］Debray D, Kelly D, Houwen R, et al. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease［J］.J Cyst Fibros, 2011,10 (2) :S29-36.
［39］Colombo C, Crosignani A, Alicandro G, et al. Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease［J］. J Pediatr,2016, 177 : 59-65.
［40］Joutsiniemi T, Timonen S, Linden M, et al. Intrahepatic cholestasis of pregnancy: observational study of the treatment with low-dose ursodeoxycholic acid［J］. BMC Gastroenterology, 2015, 15(1) : 1-7.
［41］Zhang Y, Lu L, Victor DW, et al. Ursodeoxycholic Acidand S-adenosylmethionine for the Treatment of IntrahepaticCholestasisof Pregnancy: A Meta-analysis［J］.Hepat Mon, 2016, 16(8):e38558.
［42］Xiang Z, Chen YP, Ma KF, et al. The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review［J］. BMC Gastroenterology, 2013, 13(1) : 6125-6126.
［43］Orlando R., Azzalini L, Orando S, et al. Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis［DB/OL］. Cochrane Database Syst Rev, 2007, 1(1) : CD005160.
［44］Leuschner UF, Lindenthal B, Herrmann G, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: A double-blind, randomized, placebo-controlled trial［J］. Hepatology, 2010, 52(2): 472-479.
［45］Vlad Ratziu.Treatment of NASH with ursodeoxycholic acid: Pro［J］.Clin Res Hepatol Gastroenterol, 2012, 36 (1): S41-S45.
［46］Liechti F，Dufour JF.Treatment of NASH with ursodeoxycholic acid: cons［J］.Clin Res Hepatol Gastroenterol, 2012, 36(1): S46-S52.
［47］Pelletier G, Roulot D, Davion T, et al. A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice［J］.Hepatology, 2003, 37(4): 887-892.
［48］Jacquemin E. Progressive familial intrahepatic cholestasis［J］. Clin Res Hepatol Gastroenterol, 2012, 36 (1): S26-S35.
［49］Srivastava A. Progressive Familial Intrahepatic Cholestasis［J］.J Clin Exp Hepatol, 2014, 9(6) : 594-599.
［50］Devarbhavi H. An Update on Drug-induced Liver Injury［J］.J Clin Exp Hepatol, 2012, 2 (3): 247-259.
［51］Venneman NG, Besselink MG, Keulemans YC, et al. Ursodeoxycholic Acid Exerts No Beneficial Effect in Patients With Symptomatic Gallstones Awaiting Cholecystectomy［J］. Hepatology, 2006,43(6) : 1276-1283.
［52］Reichen J. Review: Ursodeoxycholic acid does not reduce risk for mortality or liver transplantation in primary cirrhosis［J］. ACP J Club, 2008, 148(1) : 17.
［53］Vang S, Longley K, Steer CJ, et al. The Unexpected Uses of Urso-and Tauroursodeoxycholic Acid in the Treatment of Non-liver Diseases［J］.Glob Adv Health Med, 2014, 3(3):58-69.
［54］Festi D, Montagnani M, Azzaroli F, et al. Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases［J］.Curr Clin Pharmacol, 2007, 2 (2) :155-177.
［55］Proctor WR, Ming X, Bourdet D, et al. Why Does the Intestine Lack Basolateral Efflux Transporters for Cationic Compounds? A Provocative Hypothesis［J］. J Pharm Sci, 2016 105(2) : 484-496.
［56］Sies H. Oxidative stress: Oxidants and antioxidants［J］. Exp Physiol, 1997, 82(2) : 291-295.
［57］Angulo P. Use of ursodeoxycholic acid in patients with liver disease［J］. Curr Gastroenterol Rep, 2002, 4(1) : 37-44.
［58］Gaus OV, Akhmedov VA.Dynamic of clinical, laboratory and sonographic parameters after successful litholitic therapy at patients with gallstone disease in association with metabolic syndrome［J］.Eksp Klin Gastroenterol, 2015, (7) :18-23.
［59］Fiorotto R, Spirlì C, Fabris L, et al. Ursodeoxycholic Acid Stimulates Cholangiocyte Fluid Secretion in Mice via CFTR-Dependent ATP Secretion［J］. Gastroenterology, 2007, 133(5) :1603-1613.
［60］Zollner G, Marschall HU, Wagner M, et al. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: Pathogenetic and therapeutic considerations［J］. Mol Pharm, 2006, 3(3) : 231-251.
［61］Fickert P, Pollheimer MJ, Silbert D, et al. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice［J］. J Hepatol,2013, 58(6) : 1201-1208.
［62］Castro RE, Amaral JD, Sola S, et al. Differential regulation of cyclin D1 and cell death by bile acids in primary rat hepatocytes［J］. Am J Physiol Gastrointest Liver Physiol, 2007, 293(1): G327-G334.
［63］Amaral JD, Castro RE, Solá S, et al. p53 is a key molecular target of ursodeoxycholic acid in regulating apoptosis［J］. J Biol Chem, 2007, 282(47) :34250-34259.
［64］Rodrigues CM, Fan G, Wong PY, et al. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production［J］. Mol Med, 1998, 4(3) : 165-178.
［65］Utanohara S, Tsuji M, Momma S, et al. The effect of ursodeoxycholic acid on glycochenodeoxycholic acid-induced apoptosis in rat hepatocytes［J］.Toxicology, 2005, 214(2) :77-86.
［66］Fimognari C, Lenzi M, Cantelli-Forti G, et al. Apoptosis and modulation of cell cycle control by bile acids in human leukemia T cells［J］. Ann N Y Acad Sci, 2009, 1171(1) : 264-269.
［67］Hiramatsu K, Matsumoto Y, Miyazaki M, et al. Inhibition of hepatocyte growth factor production in human fibroblasts by ursodeoxycholic acid［J］. Biol Pharm Bull, 2005, 28(4) : 619-624.
［68］Tsagarakis NJ, Drygiannakis I, Batistakis  AG, et al. A concentration-dependent effect of ursodeoxycholate on apoptosis and caspases activities of HepG2 hepatocellular carcinoma cells［J］. Eur J Pharmacol, 2010, 640(3) : 1-7.
［69］Schiedermaier P, Hansen S, Asdonk D, et al. Effects of ursodeoxycholic acid on splanchnic and systemic hemodynamics. A double-blind, cross-over, placebo-controlled study in healthy volunteers［J］. Digestion, 2000, 61(2) : 107-112.
［70］Hirano S, Masuda N, Oda H.In vitro transformation of chenodeoxycholic acid and ursodeoxycholic acid by human intestinal flora, with particular reference to the mutual conversion between the two bile acids［J］. J Lipid Res, 1981, 22(5) : 735-743.
［71］ Dubreuil M,Ruiz-Gaspà S, Guaabens N, et al. Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells［J］. Liver Int, 2013, 33(7) : 1029-1038 .
［72］Kelly OB, Mroz MS, Ward JB, et al. Ursodeoxycholic acid attenuates colonic epithelial secretory function［J］.J Physiol, 2013, 591(9): 2307-2318.
［73］Solá S, Amaral JD, Aranha MM, et al. Modulation of hepatocyte apoptosis: Cross-talk between bile acids and nuclear steroid receptors［J］. Curr Med Chem, 2006, 13(25) : 3039-3051.
［74］Halilbasic E, Baghdasaryan A.Trauner M.Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases［J］. Clin Liver Dis, 2013, 17(2) : 161-189.
［75］Huang J, Plass C, Gerhauser C. Cancer chemoprevention by targeting the epigenome［J］. Curr Drug Targets, 2011, 12(13):1925-1956.
［76］Oike T, Ogiwara H, Torikai K, et al. Garcinol, a histone acetyltransferase inhibitor, radiosensitizes cancer cells by inhibiting non-homologous end joining［J］. Int J Radiat Oncol Biol Phys, 2012, 84(3):815-821.
［77］Takigawa T, Miyazaki H, Kinoshita M, et al. Glucocorticoid receptor-dependent immunomodulatory effect of ursodeoxycholic acid on liver lymphocytes in mice［J］. Am J Physiol Gastrointest Liver Physiol, 2013, 305(6) : G427-G438.
［78］Rodrigues CM, Ma X, Linehan-Stieers C, et al. Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation［J］. Cell Death Differ, 1999, 6(9) : 842-854.
［79］Rolo AP, Palmeira CM, Holy JM, et al. Role of mitochondrial dysfunction in combined bile acid-induced cytotoxicity: The switch between apoptosis and necrosis［J］. Toxicol Sci, 2004, 79(1) : 196-204.
［80］Abate N, Carubbi F, Bozzoli M, et al. Effect of chenodeoxycholic acid and ursodeoxycholic acid administration on acyl-CoA: Cholesterol acyltransferase activity in human liver［J］. Ital J Gastroenterol, 1994, 26(6) : 287-293.
［81］Weber P, Wagner M,Schneckenburger H. Fluorescence imaging of membrane dynamics in living cells［J］. J Biomed Opt, 2010, 15(15) : 046017.
［82］Sombetzki M, Fuchs CD, Fickert P, et al. 24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosisin a murine model of hepatic schistosomiasis［J］.J Hepatol, 2015, 62(4): 871-878.
［83］He H, Mennone A, Boyer JL, et al. Combination of retinoic acid and ursodeoxycholic acid attenuates liver in jury in bile duct-ligated rats and human hepatic cells［J］.Hepatology, 2011, 53(2): 548-557.